A novel RGDS-analog inhibits angiogenesis in vitro and in vivo

Biochemical and Biophysical Research Communications

Volumn 321, Issue 4, 2004, Pages 809-814

  Aguzzi, M S ^a   Facchiano, F ^a,b   Ribatti, D ^c   Gaeta, R ^d,e   Casadio, R ^f   Rossi, I ^f   Capogrossi, M C ^a   Facchiano, A ^a  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^e UNIVERSITY OF MESSINA   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Adhesion; Angiogenesis; Apoptosis; Cell matrix interactions; Endothelial cells; Integrins

Indexed keywords

ANGIOGENESIS INHIBITOR; ARGINYLGLYCYLASPARTYLSERINE; ARGINYLGLYCYLASPARTYLSERINE ANALOG MOLECULE; FIBROBLAST GROWTH FACTOR 2; SERINE DERIVATIVE; TETRAPEPTIDE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; ASSAY; CELL STRAIN; CHEMOTAXIS; CHICKEN; CHORION; CONTROLLED STUDY; DRUG MECHANISM; EGG; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR DYNAMICS; MOLECULE; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; SERUM; STATISTICAL SIGNIFICANCE;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CELL ADHESION; CELL MOVEMENT; CELLS, CULTURED; CHICK EMBRYO; DRUG STABILITY; ENDOTHELIUM, VASCULAR; HUMANS; MALE; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PHYSIOLOGIC; OLIGOPEPTIDES;

GALLUS GALLUS;

EID: 3843060180     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.07.036     Document Type: Article

References (32)

1. J.E. Meredith Jr., B. Fazeli, and M.A. Schwartz The extracellular matrix as a cell survival factor Mol. Biol. Cell. 4 1993 953 961
2. C. Brakebusch, D. Bouvard, F. Stanchi, T. Sakai, and R. Fassler Integrins in invasive growth J. Clin. Invest. 109 2002 999 1006
3. Y. Yamamoto, Y. Tsutsumi, and T. Mayumi Molecular design of bioconjugated cell adhesion peptide with a water-soluble polymeric modifier for enhancement of antimetastatic effect Curr. Drug Targets 3 2002 123 130
4. L.T. Duong, P. Lakkakorpi, I. Nakamura, and G.A. Rodan Integrins and signaling in osteoclast function Matrix. Biol. 19 2000 97 105
5. B.S. Coller Anti-GPIIb/IIIa drugs: current strategies and future directions Thromb. Haemost. 86 2001 427 443
6. D.E. Hallahan, S. Qu, L. Geng, A. Cmelak, A. Chakravarthy, W. Martin, C. Scarfone, and T. Giorgio Radiation-mediated control of drug delivery Am. J. Clin. Oncol. 24 2001 473 478
7. M.S. Aguzzi, C. Giampietri, F. De Marchis, F. Padula, R. Gaeta, G. Ragone, M.C. Capogrossi, and A. Facchiano RGDS peptide induces caspase 8 and caspase 9 activation in human endothelial cells Blood 103 2004 4180 4187
8. C.D. Buckley, D. Pilling, N.V. Henriquez, G. Parsonage, K. Threlfall, D. Scheel-Toellner, D.L. Simmons, A.N. Akbar, J.M. Lord, and M. Salmon RGD peptides induce apoptosis by direct caspase-3 activation Nature 397 1999 534 539
9. S.R. Adderley, and D.J. Fitzgerard Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation J. Biol. Chem. 275 2000 5760 5766
10. S. Castel, R. Pagan, F. Mitjans, J. Piulats, S. Goodman, A. Jonczyk, F. Huber, S. Vilaro, and M. Reina RGD peptides and monoclonal antibodies, antagonists of alpha(v)-integrin, enter the cells by independent endocytic pathways Lab. Invest. 81 2001 1615 1626
11. S.A. Mousa, J.M. Bozarth, U.P. Naik, and A. Slee Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic: distinct binding profile for Roxifiban Br. J. Pharmacol. 133 2001 331 336
12. H.U. Stilz, W. Guba, B. Jablonka, M. Just, O. Klingler, W. Konig, V. Wehner, and G. Zoller Discovery of an orally active non-peptide fibrinogen receptor antagonist based on the hydantoin scaffold J. Med. Chem. 44 2001 1158 1176
13. G.A. Sulyok, C. Gibson, S.L. Goodman, G. Holzemann, M. Wiesner, and H. Kessler Solid-phase synthesis of a nonpeptide RGD mimetic library: new selective alphavbeta3 integrin antagonists J. Med. Chem. 44 2001 1938 1950
14. 3 integrin SAR and QSAR Environ. Res. 13 2002 473 486
15. C. Bilato, K.A. Curto, R.E. Monticone, R.R. Pauly, A.J. White, and M.T. Crow The inhibition of vascular smooth muscle cell migration by peptide and antibody antagonists of the alphavbeta3 integrin complex is reversed by activated calcium/calmodulin-dependent protein kinase II J. Clin. Invest. 100 1997 693 704
16. C. Huet, C. Pisselet, B. Mandon-Pepin, P. Monget, and D. Monniaux Extracellular matrix regulates ovine granulosa cell survival, proliferation and steroidogenesis: relationships between cell shape and function J. Endocrinol. 169 2001 347 360
17. G. Bernardini, G. Spinetti, D. Ribatti, G. Camarda, L. Morbidelli, M. Ziche, A. Santoni, M.C. Capogrossi, and M. Napolitano I-309 binds to and activates endothelial cell functions and acts as an angiogenic molecule in vivo Blood 96 2000 4039 4045
18. A. Passaniti, R.M. Taylor, R. Pili, Y. Guo, P.V. Long, J.A. Haney, R.R. Pauly, D.S. Grant, and G.R. Martin A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor Lab. Invest. 67 1992 519 528
19. F. Facchiano, A. Lentini, V. Fogliano, S. Mancarella, C. Rossi, A. Facchiano, and M.C. Capogrossi Sugar-induced modification of fibroblast growth factor 2 reduces its angiogenic activity in vivo Am. J. Pathol. 161 2002 531 541
20. D. Ribatti, A. Gualandris, M. Bastaki, A. Vacca, M. Iurlaro, L. Roncali, and M. Presta New model for the study of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane: the gelatin sponge/chorioallantoic membrane assay J. Vasc. Res. 34 1997 455 463
21. G. Thumshirn, U. Hersel, S.L. Goodman, and H. Kessler Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation Chemistry 9 2003 2717 2725
22. W. Wang, R.T. Borchardt, and B. Wang Orally active peptidomimetic RGD analogs that are glycoprotein IIb/IIIa antagonists Curr. Med. Chem. 7 2000 437 453
23. A.S. Ripka, and D.H. Rich Peptidomimetic design Curr. Opin. Chem. Biol. 2 1998 441 452
24. M.A. Horton Arg-Gly-Asp (RGD) peptides and peptidomimetics as therapeutics: relevance for renal diseases Exp. Nephrol. 7 1999 178 184
25. X. Chen, R. Park, A.H. Shahinian, M. Tohme, V. Khankaldyyan, M.H. Bozorgzadeh, J.R. Bading, R. Moats, W.E. Laug, and P.S. Conti 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis Nucl. Med. Biol. 31 2004 179 189
26. J. Li, J. Ji, L.M. Holmes, K.E. Burgin, L.B. Barton, X. Yu, T.E. Wagner, and Y. Wei Fusion protein from RGD peptide and Fc fragment of mouse immunoglobulin G inhibits angiogenesis in tumor Cancer Gene Ther. 11 2004 363 370
27. M.A. Buerkle, S.A. Pahernik, A. Sutter, A. Jonczyk, K. Messmer, and M. Dellian Inhibition of the alpha-nu integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo Br. J. Cancer 86 2002 788 795
28. T. Taga, A. Suzuki, I. Gonzalez-Gomez, F.H. Gilles, M. Stins, H. Shimada, L. Barsky, K.I. Weinberg, and W.E. Laug Alpha v-integrin antagonist EMD 121974 induces apoptosis in brain tumor cells rowing on vitronectin and tenascin Int. J. Cancer 98 2002 690 697
29. D.M. Gerlag, E. Borges, P.P. Tak, H.M. Ellerby, D.E. Bredesen, R. Pasqualini, E. Ruoslahti, and G.S. Firestein Suppression of murine collagen-induced arthritis by targeted apoptosis of synovial neovasculature Arthritis Res. 3 2001 357 361
30. K. Meerovitch, F. Bergeron, L. Leblond, B. Grouix, C. Poirier, M. Bubenik, L. Chan, H. Gourdeau, T. Bowlin, and G. Attardo A novel RGD antagonist that targets both alphavbeta3 and alpha5beta1 induces apoptosis of angiogenic endothelial cells on type I collagen Vasc. Pharmacol. 40 2003 77 89
31. S.S. Srivatsa, L.A. Fitzpatrick, P.W. Tsao, T.M. Reilly, D.R. Holmes Jr., R.S. Schwartz, and S.A. Mousa Selective alpha v beta 3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: evidence for the functional importance of integrin alpha v beta 3 and osteopontin expression during neointima formation Cardiovasc. Res. 36 1997 408 428
32. C.P. Carron, D.M. Meyer, J.A. Pegg, V.W. Engleman, M.A. Nickols, S.L. Settle, W.F. Westlin, P.G. Ruminski, and G.A. Nickols A peptidomimetic antagonist of the integrin alpha(v)beta3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy Cancer Res. 58 1998 1930 1935